- Affirmative Recovery
- Alternative Dispute Resolution
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
November 30, 2020Ronald Schutz, Christopher Larus, and Cyrus Morton named in IAM Global Leaders Guide
-
November 20, 2020Phil Sieff Selected as a Fellow of the Litigation Counsel of America
-
November 20, 2020Robins Kaplan Named Breastfeeding-Friendly Workplace
-
December 1-10, 20207th Annual IP Dealmakers Forum
-
December 11, 2020LGBTQ Legal Services: Transgender Name Change Clinic
-
December 17, 2020Valuation: The “Eye of the Beholder” Causes Disputes
-
November 2020Explaining the Almost Unexplainable
-
November 12, 2020If Your Company Received a Paycheck Protection Program Loan - The SBA Wants to Know How Necessary Was Your Loan
-
November 9, 2020Hatch-Waxman Venue Is Further Narrowed
-
December 1, 2020Financial Daily Dose 12.1.2020 | Top Story: GM Adjusts Deal with Nikola, Won’t Take Stock in E-Truckmaker
-
November 30, 2020Financial Daily Dose 11.30.2020 | Top Story: Salesforce in Talks to Buy Slack Technologies
-
November 25, 2020Financial Daily Dose 11.25.2020 | Top Story: Dow Jones Hits 30,000 Mark
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
GENERICally Speaking Fall 2020
Fall 2020
The Fall 2020 issue of GENERICally Speaking provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
A few of the relevant court decisions highlighted in this issue:
- Takeda Pharms. U.S.A., Inc. v. Mylan Pharms. Inc.
Colcrys®/colchicine - IBSA Institut Biochimique, S.A. v. Teva Pharms. USA, Inc.
Tirosint®/levothyroxine sodium - Biogen Int’l Gmbh v. Amneal Pharms. LLC
Tecfidera®/dimethyl fumarate
Relevant ANDA Updates highlighted in this issue:
Reported settlements in federal district court cases
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
Tecfidera®/dimethyl fumarate
Minivelle®/estradiol transdermal system
Gilenya®/fingolimod
Riomet®/metformin HCl
Eliquis®/apixaban
Tirosint®/levothyroxine sodium
Colcrys®/colchicine
Subscribe to our quarterly GENERICally Speaking Update.
Subscribe Now
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.